Top 300 Week 1 Ambulatory Care 2026

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/55

encourage image

There's no tags or description

Looks like no tags are added yet.

56 Terms

1
New cards

Fentanyl (transdermal) brand name and class?

  • Duragesic

  • Class: Opioid Analgesic. C-II


2
New cards

Fentanyl common FDA label indication, dosing, and titration?

  • Pain, chronic, including cancer pain: adults and children > or = 2 y of age, opioid tolerant, with pain that cannot be managed by other means, transdermal fentanyl dosage based on the patient’s current 24-h oral morphine requirement; replace patch q 72 h; may replace patch q 48 h in patients not achieving adequate analgesia


3
New cards

Fentanyl (transdermal) MOA?

Fentanyl is a phenylpiperidine opioid agonist with predominant effects on the mu-opioid receptor and is about 50-100 times more potent as an analgesic than morphine.

4
New cards

Fentanyl (transdermal) box warnings?

Respiratory depression; addiction, CYP3A4/5 interactions, fatalities in children; formulations not interchangeable; care with disposal; REMS program; concurrent use with benzodiazepines or other CNS depressants, neonatal withdrawal, heat exposure with transdermal patch

5
New cards

Fentanyl (transdermal) contraindications?

Acute or postoperative pain, bronchial asthma, hypersensitivity to fentanyl, mild or intermittent pain management, opioid nontolerant patients, paralytic ileus

6
New cards

Fentanyl (transdermal) drug interactions?

  • Barbiturates, benzodiazepines, centrally acting muscle relaxants, opioids, phenothiazines → additive CNS depression → monitor and consider dose adjustments

  • Beta-blockers and calcium channel blockers → additive hypotension when combined with fentanyl anesthesia → avoid concurrent use

  • Buprenorphine, opioid mixed agonists/antagonists, opioid antagonists → precipitation of withdrawal symptoms → avoid concurrent use of opioid antagonists and opioid agonists

  • CYP3A4/5 inducers → increased fentanyl metabolism decreases fentanyl efficacy → consider dose increases of fentanyl

  • CYP3A4/5 strong/moderate inhibitors → decreased fentanyl metabolism increases risk of fentanyl toxicity → avoid concurrent use

  • MAOIs → additive respiratory depression → avoid concurrent use

  • SSRIs, SNRIs, TCAs, Triptans, linezolid → increased risk of serotonin syndrome → counsel patient on signs and symptoms of serotonin syndrome (palpitations, agitation, sweating, etc.) and to seek immediate medical attention if it develops


7
New cards

Fentanyl (transdermal) ADR?

  • Common - application site reactions, constipation, GI distress, confusion, headache, urinary retention, fatigue, edema, nausea, vomiting

  • Less common - anxiety, arrhythmias, chest pain, dyspnea, respiratory depression, upper respiratory tract infection, sweating

  • Rare but serious - stevens-johnson syndrome, physical dependence, tolerance, deafness


8
New cards

Folic acid brand name and class?

  • FA-8, True folic acid

  • Class: Essential B vitamin


9
New cards

Folic acid common FDA label indication, dosing, and titration?

  • Megaloblastic and macrocytic anemia due to folic acid deficiency: infants, 0.1 mg/d po; children age <4 y, up to 0.3 mg/d po; children > or = 4 y of age, 0.4-1 mg/d po; adults, 0.4-1 mg po daily


10
New cards

Folic acid MOA?

Folic acid is required for the conversion of deoxyuridylate to thymidylate, which is a rate-limiting step in DNA synthesis. Folic acid deficiency presents clinically as macrocytic anemia when red blood cells are unable to extrude their nucleus.

11
New cards

Folic acid box warnings?

None

12
New cards

Folic acid contraindications?

Hypersensitivity

13
New cards

Folic acid drug interactions?

  • Barbiturates → decreased folic acid absorption; increases barbiturate metabolism and less efficacy → monitor barbiturate efficacy

  • Phenytoin → decreased folic acid serum levels; decreased phenytoin effectiveness → monitor for seizure control

  • Pyrimethamine → decreased efficacy of sulfadoxine/pyrimethamine, leading to treatment failure → avoid folic acid doses > 2.5 mg/d


14
New cards

Folic acid ADR?

  • Common - loss of appetite

  • Less common - confusion, irritation

  • Rare but serious - anaphylaxis


15
New cards

Gabapentin brand name and class?

  • Neurontin, Gralise

  • Class: Gamma Aminobutyric Acid Analog, Anticonvulsant


16
New cards

Gabapentin common FDA label indication, dosing, and titration?

  • Partial seizure, adjunct: immediate release, adults and children > or = 12 y of age, initial, 300 mg po tid, may titrate to 1800 mg/d in 3 divided doses (max 2400-3600 mg/d); children 3-11 y of age, initial, 10-15 mg/kg/d divided in 3 doses maintenance (Children 3-4 y of age), may titrate over 3 d to 40 mg/kg/d in 3 divided doses, maintenance (Children 5-11 y of age), may titrate over 3 d to 25-35 mg/kg/d in 3 divided doses

  • Postherpetic neuralgia: immediate release, adults, 300 mg po on day 1, 300 mg bid on day 2, 300 mg tid on day 3, may titrate dose to 1800-3600 mg/d in 3 divided doses; ER, 300 mg on day 1, 600 mg on day 2, 900 mg days 3-6, 1200 mg days 7-10, 1500 mg days 11-14, and 1800 mg po daily thereafter


17
New cards

Gabapentin MOA?

Gabapentin is a cyclohexane compound that is structurally related to GABA; its mechanism of action is not known. Gabapentin does not interact with GABA receptors or alter the formation, release, degradation, or reuptake of GABA.

18
New cards

Gabapentin box warnings?

None

19
New cards

Gabapentin contraindications?

Hypersensitivity

20
New cards

Gabapentin drug interactions?

  • Antacids → decreased gabapentin absorption → separate administration by 2 hours

  • CNS depressants (alcohol, hypnotics, opioids) → enhance the sedative effect → advise patients to use cautiously or not at all


21
New cards

Gabapentin ADR?

  • Common - ataxia, dizziness, somnolence, fatigue

  • Less common - blurred vision, diarrhea, hostile behavior, peripheral edema, nausea, nystagmus, vomiting, weight gain, xerostomia

  • Rare but serious - Stevens’s-Johnson syndrome, suicidal thoughts


22
New cards

Glimepiride brand name and class?

  • Amaryl

  • Class: Second-generation Sulfonylurea, Antidiabetic


23
New cards

Glimepiride common FDA label indication, and dosing?

  • Diabetes-mellitus, type 2: 1-2 mg po daily, may titrate by 1-2 mg every 1-2 wk to effect, max dose 8 mg po daily


24
New cards

Glimepiride MOA?

Sulfonylureas enhance insulin secretion from pancreatic β-cells and potentiate insulin action on several extrahepatic tissues. Long-term sulfonylureas increase peripheral utilization of glucose, suppress hepatic gluconeogenesis, and possibly increase the sensitivity and/or number of peripheral insulin receptors.

25
New cards

Glimepiride box warnings?

None

26
New cards

Glimepiride contraindications?

Hypersensitivity to sulfonylureas, diabetic ketoacidosis

27
New cards

Glimepiride drug interactions?

  • Beta-blockers → altered glucose metabolism and increased risk of hypoglycemia, symptoms of hypoglycemia masked → avoid concurrent propranolol; use others with caution and increased monitoring

  • CYP2C9 inducers → increased glimepiride metabolism and decreased glimepiride efficacy → monitor blood glucose and consider dose increases of glimepiride

  • CYP2C9 inhibitors → decreased glimepiride metabolism and increased risk of glimepiride toxicity → monitor blood glucose and consider dose decreases of glimepiride

  • Fluoroquinolones, NSAIDs, Fenofibrate, SSRIs, somatostatin analogues → altered glucose metabolism and increased risk of hypoglycemia and hyperglycemia → avoid concurrent use if possible; monitor and consider dose adjustments

  • MAOIs → stimulation of insulin secretion, hypoglycemic effects → avoid concurrent use if possible; monitor and consider dose adjustments

  • Psyllium → psyllium may delay absorption of glucose from meals, increasing hypoglycemic effects → avoid concurrent use if possible; monitor and consider dose adjustments

  • Sulfonamides, GLP-1 RA, SGLT2 inhibitors, insulin → increased risk of hypoglycemia → monitor blood glucose and consider dose adjustments


28
New cards

Glimepride ADR?

  • Common - none known

  • Less common - hypoglycemia, nausea, headache, dizziness and asthenia, and increased LFTs

  • Rare but serious - cutaneous hypersensitivity, hemolytic anemia, hepatotoxicity, disulfiram interactions


29
New cards

Glipizide brand name and class?

  • Glucotrol

  • Class: Second-generation Sulfonylurea, Antidiabetic


30
New cards

Glipizide common FDA label indication, dosing, and titration?

  • Diabetes mellitus: immediate release, 2.5-5 mg po daily, may titrate to max 40 mg po daily, divide bid if doses > 15 mg; extended-release, 2.5-5 mg po daily, may titrate to max 20 mg po daily


31
New cards

Glipizide MOA?

Sulfonylureas enhance insulin secretion from pancreatic β-cells and potentiate insulin action on several extrahepatic tissues. Long-term sulfonylureas increase peripheral utilization of glucose, suppress hepatic gluconeogenesis, and possibly increase the sensitivity and/or number of peripheral insulin receptors.

32
New cards

Glipizide box warnings?

None

33
New cards

Glipizide contraindications?

Hypersensitivity to sulfonylureas, diabetic ketoacidosis, type 1 diabetes

34
New cards

Glipizide drug interactions?

  • Beta-blockers → altered glucose metabolism and increased risk of hypoglycemia, symptoms of hypoglycemia masked → avoid concurrent propranolol; use others with caution and increased monitoring

  • CYP2C9 inducers → increased glipizide metabolism and decreased glipizide efficacy → monitor blood glucose and consider dose increases of glipizide

  • CYP2C9 inhibitors → decreased glipizide metabolism and increased risk of glipizide toxicity → monitor blood glucose and consider dose decreases of glipizide

  • Fluoroquinolones, NSAIDs, Fenofibrate, SSRIs, somatostatin analogues → altered glucose metabolism and increased risk of hypoglycemia and hyperglycemia → avoid concurrent use if possible; monitor and consider dose adjustments

  • MAOIs → stimulation of insulin secretion, hypoglycemic effects → avoid concurrent use if possible; monitor and consider dose adjustments

  • Psyllium → psyllium may delay absorption of glucose from meals, increasing hypoglycemic effects → avoid concurrent use if possible; monitor and consider dose adjustments

  • Sulfonamides, GLP-1 RA, SGLT2 inhibitors, insulin → increased risk of hypoglycemia → monitor blood glucose and consider dose adjustments



35
New cards

Glipizide ADR?

  • Common - asthenia

  • Less common - hypoglycemia, nausea, headache, tremors, constipation, diarrhea, dizziness, nervousness, tremor

  • Rare but serious - cutaneous hypersensitivity, hemolytic anemia, hepatotoxicity, disulfiram reaction


36
New cards

Hydrocodone brand name and class?

  • Norco, Lorset, Vicodin, Hysingla ER

  • Opioid Analgesic. C-II


37
New cards

Hydrocodone common FDA label indication, dosing, and titration?

  • Pain, severe: adults, 12 h extended release capsule, 10 mg q12h initially, may titrate to response; 24 h extended release tablet, 20 mg po daily, may titrate to response


38
New cards

Hydrocodone MOA?

Hydrocodone binds to opiate receptors, resulting in altered perception of pain.

39
New cards

Hydrocodone box warnings?

Addiction, abuse, misuse, REMS, respiratory depression, accidental ingestion, neonatal opioid withdrawal, alcohol, CYP3A4/5 interactions, hepatotoxicity, concurrent use with benzodiazepines

40
New cards

Hydrocodone contraindications?

Hypersensitivity, paralytic ileus, respiratory depression, severe asthma

41
New cards

Hydrocodone drug interactions?

  • Barbiturates, benzodiazepines, centrally acting muscle relaxants, phenothiazines, hydroxyzine → additive CNS depression → avoid concurrent use with opioids

  • Buprenorphine, opioid mixed agonists/antagonists, opioid antagonists → precipitation of withdrawal symptoms → avoid concurrent use with opioids

  • CYP3A4/5 inducers → Increased hydrocodone metabolism decreases hydrocodone efficacy → Monitor and consider hydrocodone dose increase

  • CYP2D6 inhibitors → Decreased activation of hydrocodone to hydromorphone, decreased hydrocodone efficacy → Monitor and consider dose increases of hydrocodone

  • MAOIs → Additive respiratory depression and increased risk of serotonin syndrome → Avoid concurrent use

  • SSRIs, SNRIs, TCAs, triptans → Increased risk of serotonin syndrome → Counsel patient on signs and symptoms of serotonin syndrome (palpitations, agitation, sweating, etc.) and to seek immediate medical attention if it develops


42
New cards

Hydrocodone ADR?

  • Common - constipation, GI distress, somnolence

  • Less common - rash, respiratory depression, euphoria, pruritus, dizziness, chest pain

  • Rare but serious - Stevens-Johnson syndrome, physical dependence, tolerance, respiratory depression, serotonin syndrome, adrenal insufficiency, decreased sex hormones


43
New cards

Ibrandronate brand name and class?

  • Boniva

  • Class: Bisphosphonate


44
New cards

Ibandronate common FDA label indication, dosing, and titration?

  • Postmenopausal osteoporosis (treatment): 150 mg po once monthly

  • Postmenopausal osteoporosis (prophylaxis): 150 mg po once monthly


45
New cards

Ibandronate MOA?

Ibandronate binds to bone hydroxyapatite and, at the cellular level, inhibits osteoclast activity, thereby modulating bone metabolism.

46
New cards

Ibandronate box warnings?

None

47
New cards

Ibandronate contraindications?

Esophageal abnormalities, which delay esophageal emptying, hypocalcemia, inability to sit or stand upright for at least 60 min

48
New cards

Ibandronate drug interactions?

  • Aluminum, calcium-containing products → Decreased bisphosphonate absorption → Separate administration by 1-2 h

  • H2-blockers and PPIs → Decreased bisphosphonate absorption → Separate administration by 12-24 h

  • NSAIDs → Increased gastric and renal toxicity → Monitor for toxicity when used concurrently


49
New cards

Ibandronate ADR?

  • Common - Indigestion, backache, respiratory tract infections

  • Less common - HTN, diarrhea, abdominal pain, headache, myalgia

  • Rare but serious - Osteonecrosis of the jaw, esophageal cancer, esophageal ulcers, immune hypersensitivity, arrhythmia, bone fractures, severe muscle pain


50
New cards

Glyburide brand name and class?

  • Glynase

  • Class: Second-Generation Sulfonylurea, Antidiabetic


51
New cards

Glyburide common FDA label indication, dosing, and titration?

  • Diabetes mellitus, type II: 1.25-20 mg po daily; titrate to effect, max dose 20 mg po daily


52
New cards

Glyburide MOA?

Sulfonylureas enhance insulin secretion from pancreatic β-cells and potentiate insulin action on several extrahepatic tissues. Long-term sulfonylureas increase peripheral utilization of glucose, suppress hepatic gluconeogenesis, and possibly increase the sensitivity and/or number of peripheral insulin receptors.

53
New cards

Glyburide box warnings?

None

54
New cards

Glyburide contraindications?

Hypersensitivity to sulfonylureas, diabetic ketoacidosis, Type I diabetes, concurrent bosentan

55
New cards

Glyburide drug interactions?

  • Beta-blockers → Altered glucose metabolism and increased risk of hypoglycemia. Symptoms of hypoglycemia masked → Avoid propranolol, use others with caution and increased monitoring

  • Bosentan → Glyburide may enhance the hepatotoxic effect of bosentan. Bosentan may increase the metabolism of glyburide → Contraindicated

  • CYP2C9 inducers → Induction of sulfonylureas metabolism by inducers and decreased sulfonylureas levels → Monitor blood glucose and consider dose adjustments of sulfonylureas

  • CYP2C9 inhibitors → Inhibition of sulfonylureas metabolism by inhibitors and increased sulfonylureas levels → Monitor blood glucose and consider dose adjustments of sulfonylureas

  • Fluoroquinolones, NSAIDs, fenofibrate, SSRIs, somatostatin analogues → Altered glucose metabolism and increased risk of hypoglycemia and hyperglycemia → Avoid concurrent use if possible; monitor and consider dose adjustments

  • MAOIs → Stimulation of insulin secretion, hypoglycemic effects → Avoid concurrent use if possible; monitor and consider dose adjustments

  • Psyllium → Psyllium may delay absorption of glucose from meals → Avoid concurrent use if possible; monitor and consider dose adjustments

  • Sulfonamides → Increased risk of hypoglycemia → Monitor blood glucose and consider dose adjustments of sulfonylureas


56
New cards

Glyburide ADR?

  • Common - Nocturnal enuresis

  • Less common - Hypoglycemia, nausea, myalgia, skin rash, heartburn

  • Rare but serious - Cutaneous hypersensitivity, hemolytic anemia, disulfiram reaction